Skip to main content

ENTRESTO® supports your eligible heart failure patients with options to help them start and stay on treatment as prescribed

Patient access

We’re committed to helping make ENTRESTO affordable for patients. ENTRESTO has the lowest branded co-pay for more than 99% of eligible patients1

Two ways eligible patients can have access to ENTRESTO

Patients can text to enroll for information about the 30-day Free Trial Offer and $10 Co-pay programs

Free Trial Offer available for all patients

AVAILABLE TO ALL PATIENTS

Regardless of insurance, patients can access a 30-day free trial offer,
pre-activated and ready to use when initiating treatment. 

$10 Co-Pay Card for eligible commercially insured patients

$10 CO-PAY OFFER FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS

Eligible commercially insured patients may pay as little as $10 for up to a
90-day supply of ENTRESTO.§

Limitations apply. See full Terms and Conditions below.
Limitations apply. This voucher is good for a 30-day (maximum 60 tablets; one-time use) free trial of ENTRESTO at no cost for your patient. See full Terms and Conditions below.
§Limitations apply. See Program Terms and Conditions. Eligible commercial patients pay as little as a $10 co-pay for each prescription fill (30-, 60-, 90-day fill) at retail or mail order. The program pays up to a $4100 cap across all fills per calendar year. Patient will be responsible for any co-pay once the $4100 limit is reached in a calendar year. This offer is not valid under Medicare, Medicaid, or any other federal or state program. See full Terms and Conditions below.

Help your patients get access to ENTRESTO by visiting Entresto-Coverage.com for helpful tools and resources, including:

  • Comprehensive information on health plan coverage, criteria, and more 

  • Coverage breakdowns by health plan with prior authorization requirements 

  • Blank plan-specific prior authorization forms available for download 

View coverage

Find out information your patients need to know about Medicare coverage for ENTRESTO, visit MyCoverageResource.com to get:

  • Information on which Medicare plan covers ENTRESTO 

  • Publicly available information about Medicare 

  • Important Medicare Part D updates

Visit

Discover the ENSPIRE Program from ENTRESTO® 

The ENSPIRE Program from ENTRESTO®, a free 12-month lifestyle and treatment support program, is designed to help your patients lead a healthier life. ENSPIRE provides them with a range of support resources and more: 

  • Dietary recommendations 

  • Heart-healthy lifestyle advice 

  • Medication management 

  • Tips and tools to manage symptoms 

  • Activity tracking 

Learn more

FOR YOUR PATIENTS WITH LIMITED OR NO PRESCRIPTION COVERAGE, THEY MAY QUALIFY FOR HELP FROM NOVARTIS PATIENT ASSISTANCE FOUNDATION (NPAF)

NPAF, a nonprofit organization, is committed to providing access to Novartis medications for those most in need. If your patient is experiencing financial hardship, has limited or no prescription coverage, and cannot afford the cost of their medications, then they may be eligible to receive Novartis medications for free. To learn more, call 1-800-277-2254 or visit www.PAP.Novartis.com

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.2

Important Safety Information

BOXED WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue ENTRESTO as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

ENTRESTO is contraindicated in patients with hypersensitivity to any component...

Indication

ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.

LVEF is a variable measure, so use clinical judgment in deciding whom to treat.

Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

References
1. Data on file. Novartis Pharmaceuticals Corp; 2022.
2. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.